Manual of clinical psychopharmacology
Title:
Manual of clinical psychopharmacology
Author:
ISBN:
9780880489218
Edition:
3rd ed
Publication Information:
Washington, DC : American Psychiatric Press, c1997
Physical Description:
xxii, 477 p. : ill. ; 21 cm
Available:
Library | Call Number | Material Type | Status |
---|---|---|---|
Searching... State Library of Oregon | 616.8918 Schat | 4-Week Loan | Searching... Unknown |
Bound With These Titles
On Order
Summary
Summary
Provides concise and updated guidance in the selection and prescription of appropriate drug therapies for individual patients. Reviews all classes of psychiatric medications, including new drugs such as olanzapine, sertindole, gabapentin, mirtazapine, and venlafaxine.
Table of Contents
Preface | p. xxiii |
1 General Principles of Psychopharmacological Treatment | p. 1 |
General Advice | p. 3 |
Practice Guidelines | p. 4 |
Legal, Ethical, and Economic Issues | p. 4 |
Bibliography | p. 12 |
2 Diagnosis and Classification | p. 15 |
Mood Disorders | p. 17 |
Bipolar Disorders | p. 17 |
Depressive Disorders | p. 19 |
Schizophrenia and Other Schizophrenia Spectrum Disorders | p. 22 |
Anxiety Disorders | p. 24 |
Somatoform Disorders | p. 28 |
Personality Disorders | p. 28 |
Psychoactive Substance Use Disorders | p. 29 |
Child and Adolescent Disorders | p. 30 |
FDA Approval of Symptom Reduction Strategies | p. 31 |
DSM-V and Pharmacogenetics | p. 31 |
Summary | p. 32 |
Bibliography | p. 32 |
3 Antidepressants | p. 35 |
History | p. 38 |
General Principles of Antidepressant Use | p. 40 |
Choosing an Antidepressant | p. 40 |
Dosage and Administration | p. 44 |
Duration of Treatment | p. 44 |
Selective Serotonin Reuptake Inhibitors | p. 46 |
Pharmacological Effects | p. 46 |
Indications | p. 51 |
Side Effects | p. 54 |
Overdose | p. 61 |
Drug Interactions | p. 61 |
Dosage and Administration | p. 53 |
Discontinuation | p. 67 |
5-HT[subscript 2] Receptor Antagonists (Trazodone and Nefazodone) | p. 69 |
Pharmacological Effects | p. 70 |
Indications | p. 71 |
Side Effects | p. 72 |
Overdose | p. 75 |
Drug Interactions | p. 76 |
Dosage and Administration | p. 77 |
Discontinuation | p. 78 |
Selective Serotonin-Norepinephrine Reuptake Inhibitors (Venlafaxine and Duloxetine) | p. 78 |
Pharmacological Effects | p. 79 |
Indications | p. 80 |
Side Effects | p. 82 |
Overdose | p. 83 |
Drug Interactions | p. 83 |
Dosage and Administration | p. 84 |
Discontinuation | p. 85 |
Combined Noradrenergic-Dopaminergic Antidepressant (Bupropion) | p. 85 |
Pharmacological Effects | p. 86 |
Indications | p. 87 |
Side Effects | p. 89 |
Overdose | p. 89 |
Drug Interactions | p. 90 |
Dosage and Administration | p. 90 |
Mirtazapine | p. 90 |
Pharmacological Effects | p. 90 |
Indications | p. 92 |
Side Effects | p. 93 |
Overdose | p. 95 |
Drug Interactions | p. 95 |
Dosage and Administration | p. 95 |
Norepinephrine Reuptake Inhibitors: Reboxetine and Atomoxetine | p. 96 |
Pharmacological Effects | p. 96 |
Indications | p. 97 |
Side Effects | p. 98 |
Overdose | p. 99 |
Dosage and Administration | p. 99 |
Drug Interactions | p. 99 |
Discontinuation | p. 99 |
Gepirone | p. 100 |
Tricyclic and Tetracyclic Antidepressants | p. 101 |
Structures | p. 101 |
Pharmacological Effects | p. 101 |
Indications | p. 106 |
Blood Levels | p. 107 |
Side Effects | p. 112 |
Overdose | p. 115 |
Dosage and Administration | p. 115 |
Discontinuation | p. 117 |
Monoamine Oxidase Inhibitors | p. 118 |
Pharmacological Effects | p. 118 |
Indications | p. 118 |
Side Effects | p. 121 |
Overdose | p. 125 |
Drug Interactions | p. 125 |
Dosage and Administration | p. 128 |
Discontinuation | p. 128 |
Selective and Reversible Monoamine Oxidase Inhibitors | p. 129 |
Melatonin Agonist-5-HT[subscript 2C] Antagonist | p. 133 |
Novel Antidepressants | p. 134 |
Bibliography | p. 136 |
4 Antipsychotic Drugs | p. 159 |
General Principles of Antipsychotic Use | p. 162 |
The Drugs | p. 162 |
Efficacy | p. 168 |
Acute Antipsychotic Treatment | p. 171 |
Early Inpatient Treatment | p. 175 |
Maintenance Drug Therapy | p. 178 |
Use in Other Psychiatric Disorders | p. 182 |
Atypical Antipsychotics | p. 189 |
Clozapine | p. 189 |
Risperidone | p. 200 |
Olanzapine | p. 203 |
Quetiapine | p. 207 |
Ziprasidone | p. 210 |
Aripiprazole | p. 212 |
Standard (Typical) Antipsychotics | p. 214 |
Side Effects | p. 216 |
Haloperidol Decanoate | p. 231 |
Other Options for Treating Negative Symptoms | p. 232 |
Alternatives to Antipsychotic Therapy | p. 234 |
Antipsychotic Drugs in Development | p. 236 |
Bibliography | p. 238 |
5 Mood Stabilizers | p. 255 |
Lithium | p. 257 |
History and Indications | p. 257 |
Pharmacological Effects | p. 261 |
Clinical Indications | p. 262 |
Side Effects | p. 269 |
Preparations | p. 276 |
Dosage and Administration | p. 277 |
Use in Pregnancy | p. 279 |
Lithium Information Center | p. 280 |
Anticonvulsants | p. 280 |
Valproate | p. 281 |
Carbamazepine | p. 294 |
Lamotrigine | p. 301 |
Other Anticonvulsants | p. 306 |
Antipsychotics | p. 317 |
Benzodiazepines | p. 319 |
Calcium Channel Blockers | p. 320 |
Omega-3 Fatty Acids | p. 321 |
Bibliography | p. 322 |
6 Antianxiety Agents | p. 337 |
Benzodiazepines | p. 340 |
Indications | p. 340 |
Pharmacological Effects | p. 342 |
Subclasses | p. 343 |
Dosage and Administration | p. 348 |
Withdrawal | p. 352 |
Side Effects | p. 355 |
Overdose | p. 355 |
Antidepressants | p. 356 |
Agoraphobia and Panic | p. 356 |
Generalized Anxiety Disorder | p. 357 |
Social Phobia | p. 358 |
Body Dysmorphic Disorder | p. 360 |
Posttraumatic Stress Disorder | p. 360 |
Obsessive-Compulsive Disorder | p. 364 |
Anticonvulsants | p. 366 |
Antipsychotics | p. 368 |
Noradrenergic Agents | p. 369 |
Clinical Indications | p. 369 |
Dosage and Administration | p. 370 |
Side Effects | p. 371 |
Antihistamines | p. 372 |
Buspirone | p. 372 |
Barbiturates | p. 375 |
Amobarbital Sodium (Amytal) as a Parenteral Solution | p. 377 |
Catatonia | p. 382 |
Meprobamate | p. 384 |
Bibliography | p. 386 |
7 Hypnotics | p. 395 |
Insomnia | p. 395 |
Behavioral Approaches | p. 401 |
Pharmacological Approaches | p. 401 |
Benzodiazepine Hypnotics | p. 403 |
Nonbenzodiazepine Hypnotics | p. 409 |
Melatonin Receptor Agonist: Ramelteon | p. 411 |
Sedative Antihistamines and Other Nonbenzodiazepine Psychoactive Drugs With Hypnotic Properties | p. 412 |
Barbiturates | p. 414 |
Nonbarbiturate Hypnotics | p. 417 |
Methaqualone | p. 419 |
Over-the-Counter Sleeping Agents | p. 420 |
L-Tryptophan | p. 420 |
Melatonin | p. 421 |
Valerian Extract | p. 422 |
General Conclusions | p. 423 |
Bibliography | p. 425 |
8 Stimulants and Other Fast-Acting Drugs | p. 429 |
Amphetamine Abuse | p. 434 |
Uses of Stimulants | p. 436 |
Attention-Deficit/Hyperactivity Disorder | p. 436 |
Depression | p. 439 |
Acquired Immunodeficiency Syndrome | p. 443 |
Other Medical Conditions | p. 444 |
Drug Combinations | p. 444 |
Psychosis | p. 445 |
Stimulant Use Versus Abuse | p. 446 |
Other Fast-Acting Drugs | p. 447 |
Bibliography | p. 449 |
9 Augmentation Strategies for Treatment-Resistant Disorders | p. 453 |
Augmentation Strategies for Depression | p. 454 |
Lithium-Antidepressant Combinations | p. 454 |
Thyroid Supplement-Antidepressant Combinations | p. 457 |
Estrogen, DHEA, and Testosterone Combinations With Antidepressants | p. 460 |
Dopamine Agonist-Antidepressant Combinations | p. 463 |
Monoamine Precursor-Antidepressant Combinations | p. 464 |
SSRI Combinations | p. 465 |
Antipsychotic-Antidepressant Combinations | p. 469 |
Other TCA Combinations | p. 471 |
Augmentation Strategies for Bipolar Disorder | p. 473 |
Combinations of Two or More Mood Stabilizers | p. 473 |
Mood Stabilizer-Antipsychotic Combinations | p. 475 |
Mood Stabilizer-Antidepressant Combinations | p. 477 |
Mood Stabilizers and Omega-3 Fatty Acids | p. 478 |
Augmentation Strategies for Schizophrenia | p. 479 |
Combinations of Two Antipsychotics | p. 479 |
Combinations of Antidepressants and Antipsychotics | p. 480 |
Combinations of Mood Stabilizers and Antipsychotics | p. 481 |
Other Augmentation Strategies | p. 483 |
Bibliography | p. 484 |
10 Emergency Room Treatment | p. 499 |
Agitation and Violence | p. 500 |
Depression and Suicidality | p. 504 |
Acute Psychotic Reactions | p. 508 |
Mixed Psychotic Reactions | p. 508 |
Schizophrenic, Schizophreniform, and Manic Psychoses | p. 509 |
Delirium | p. 511 |
Severe Anxiety | p. 512 |
Stupor and Catatonia | p. 513 |
Emergency Room Referrals | p. 514 |
Bibliography | p. 515 |
11 Pharmacotherapy for Substance Use Disorders | p. 519 |
Drug Testing | p. 521 |
Stimulants | p. 522 |
Opiates | p. 523 |
Detoxification | p. 523 |
Maintenance | p. 526 |
Sedatives and Hypnotics | p. 530 |
Detoxification | p. 530 |
Pentobarbital Tolerance Test | p. 531 |
Benzodiazepines | p. 532 |
Alcohol | p. 534 |
Maintenance Treatment | p. 537 |
Cannabis | p. 541 |
Hallucinogens | p. 542 |
Phencyclidine | p. 542 |
Bibliography | p. 543 |
12 Pharmacotherapy in Special Situations | p. 549 |
Pregnancy | p. 549 |
Pediatric Psychopharmacology | p. 556 |
Stimulants | p. 557 |
Antipsychotics | p. 561 |
Antidepressants | p. 565 |
Mood Stabilizers | p. 568 |
Antianxiety Drugs | p. 570 |
Geriatric Psychopharmacology | p. 571 |
Antidepressants | p. 572 |
Hypnotics and Anxiolytics | p. 574 |
Mood Stabilizers | p. 575 |
Antipsychotics | p. 576 |
Medications for Dementia | p. 578 |
Medications for Agitation | p. 582 |
Mental Retardation | p. 584 |
Medical Conditions | p. 587 |
Psychiatric Disorders Resulting From Medical Illness | p. 587 |
Psychiatric Disorders Associated With Nonpsychiatric Drugs | p. 590 |
Psychiatric Disorders Complicated by Medical Disorders | p. 591 |
Conclusion | p. 601 |
Bibliography | p. 601 |
13 Herbals and Dietary Supplements | p. 619 |
St. John's Wort (Hypericum Perforatum) | p. 621 |
Uses | p. 623 |
Mechanism of Action | p. 624 |
Side Effects and Drug Interactions | p. 624 |
Dosage and Administration | p. 625 |
Omega-3 Fatty Acids | p. 625 |
Uses and Mechanism of Action | p. 626 |
Side Effects and Drug Interactions | p. 626 |
Dosage and Administration | p. 627 |
Kava (Piper Methysticum) | p. 627 |
Uses | p. 627 |
Mechanism of Action | p. 627 |
Side Effects and Drug Interactions | p. 628 |
Dosage and Administration | p. 628 |
Valerian (Valeriana Officinalis) | p. 629 |
Uses | p. 629 |
Mechanism of Action | p. 629 |
Side Effects and Drug Interactions | p. 629 |
Dosage and Administration | p. 630 |
Ginkgo (Ginkgo Biloba) | p. 630 |
Uses | p. 630 |
Mechanism of Action | p. 630 |
Side Effects and Drug Interactions | p. 630 |
Dosage and Administration | p. 631 |
Folate and B Vitamins | p. 631 |
S-Adenosylmethionine (SAMe) | p. 632 |
Uses | p. 632 |
Mechanism of Action | p. 633 |
Side Effects and Drug Interactions | p. 633 |
Dosage and Administration | p. 633 |
Inositol | p. 634 |
Uses | p. 634 |
Mechanism of Action | p. 634 |
Side Effects and Drug Interactions | p. 635 |
Dosage and Administration | p. 635 |
DHEA (Dehydroepiandrosterone) | p. 635 |
Uses | p. 635 |
Mechanism of Action | p. 636 |
Side Effects and Drug Interactions | p. 636 |
Dosage and Administration | p. 636 |
Bibliography | p. 636 |
Appendix A Strengths and Costs of Antidepressant and Antipsychotic Drugs | p. 641 |
Appendix B Suggested Readings | p. 645 |
Index | p. 647 |
SD_ILS:839922
Cole, Jonathan O.
Schatzberg, Alan F.
9780880489218
Select a list
The following items were successfully added.
There was an error while adding the following items. Please try again.
One or more items could not be added because you are not logged in.